deferoxamine has been researched along with vlx600 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brandt, P; Bremberg, U; D'Arcy, P; Fryknäs, M; Gullbo, J; Larsson, R; Linder, S; Nygren, P; Olofsson, MH; Persson, I; Schughart, LK; Senkowski, W; Zhang, X | 1 |
1 other study(ies) available for deferoxamine and vlx600
Article | Year |
---|---|
Iron chelators target both proliferating and quiescent cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deferoxamine; Dose-Response Relationship, Drug; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Inhibitory Concentration 50; Iron Chelating Agents; MCF-7 Cells; Mitochondria; Ribonucleotide Reductases; Structure-Activity Relationship; Triazoles | 2016 |